28 Aug 2019 07:00
28 August 2019
Collagen Solutions plc
("Collagen Solutions" or the "Company")
AGM Statement
Delivering on our growth strategy
Collagen Solutions plc (AIM: COS), the developer and manufacturer of biomaterials and regenerative medicines for the enhancement and extension of human life, will hold its Annual General Meeting at 11am today at their offices at 3 Robroyston Oval, Nova Business Park, Glasgow, G33 1AP. At the meeting, Jamal Rushdy, CEO of Collagen Solutions will make the following statement:
"Building on a successful fundraise in June, and momentum from our most recent financial year, we remain positive about our outlook and on track with our key initiatives for the year. Our core business is seeing continued growth as expected to support our goal of further improvement on overall financial performance in line with market expectations. We are also progressing with infrastructure projects to increase our capacity for contract manufacturing while we also expand our tissue supply. We are engaged in active dialogue with our notified body regarding our application for CE marking ChondroMimetic®, consistent with our plan to resolve open questions in time to gain approval in the financial year, while the response time or additional questions by the notified body still cannot be guaranteed. Finally, our global R&D team is executing on several key customer product development projects supporting a strong pipeline of contract manufacturing over the next several years."
Collagen Solutions Plc |
| |||
Jamal Rushdy, CEO | Via Walbrook | |||
Hilary Spence, CFO |
| |||
|
| |||
Cenkos Securities Plc (Nominated Adviser and Broker) |
| |||
Giles Balleny | Tel: 0207 397 8900 | |||
Stephen Keys |
| |||
|
| |||
Walbrook PR Ltd | Tel: 020 7933 8780 or collagen@walbrookpr.com | |||
Anna Dunphy | Mob: 07876 741 001 | |||
About Collagen Solutions:
Collagen Solutions Plc is a global supplier, developer, and manufacturer of medical grade collagen, tissues, and related medical devices and components for use in regenerative medicine, tissue engineering, and research. The Company is also expanding its range of biomaterials-based finished medical devices based on its internal and acquired intellectual property for commercialisation with partners via licensing and distribution arrangements, including ChondroMimetic®. The Company's products are used in a wide variety of applications including orthopaedics, cardiovascular, dental, plastic surgery, wound healing, neurology and urology.
For more information go to: www.collagensolutions.com